Non-destructive luminescence and PET imaging to monitor tissue microenvironment in microphysiological systems during brain metastasis using dissociated cerebral organoids
Source abstract
Abstract
Abstract During brain metastasis, tumor cells interact with the surrounding stroma, including neurons and astrocytes, to create a tumor-promoting microenvironment. However, the molecular and cellular factors driving tumor-neural stroma interactions remain unclear. Here, we developed a co-culture model of metastatic melanoma by combining metastatic melanoma cells with dissociated human iPSC-derived cerebral organoids, consisting of neurons and astrocytes, in a microfluidic device. We cultured these astrocytes and neurons in a 3D hydrogel that contained a domain with metastatic melanoma cells. This approach generated a spatially organized co-culture system with no physical boundary between the tumor and stromal compartments. Then, we leveraged several imaging modalities to study tumor-stroma interactions and changes in the microenvironment. Using non-destructive, luminescence-based methods, we spatially resolved changes in cell viability, metabolite concentration, and other biochemical parameters. We also used luminescence to analyze the effect of radionuclides on tumor cell viability and used PET imaging to monitor their diffusion across the system.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: 3D Printing in Biomedical Research · Chemical Reactions and Isotopes · bioluminescence and chemiluminescence research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (65)
Show source-provided references
1. Role of the nervous system in cancer metastasis10.1186/s13046-018-0674-x ↗
2. The emerging role of amino acids of the brain microenvironment in the process of metastasis formation10.3390/cancers13122891 ↗
3. Molecular insights into melanoma brain metastases10.1002/cncr.30594 ↗
4. Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies10.1002/cncr.33459 ↗
5. Neuronal cannabinoid CB1 receptors suppress the growth of melanoma brain metastases by inhibiting glutamatergic signalling10.3390/cancers15092439 ↗
6. Dissecting the treatment-naive ecosystem of human melanoma brain metastasis10.1016/j.cell.2022.06.007 ↗
7. Ganglioside GD2 enhances the malignant phenotypes of melanoma cells by cooperating with integrins10.3390/ijms23010423 ↗
8. Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients10.1186/s13045-017-0548-2 ↗
9. Incipient melanoma brain metastases instigate astrogliosis and neuroinflammation10.1158/0008-5472.CAN-16-0485 ↗
10. Melanoma brain metastases: biological basis and novel therapeutic strategies10.1111/exd.14286 ↗
11. Dissecting the brain with spatially resolved multi-omics10.1016/j.jpha.2023.04.003 ↗
12. The topographic brain: from neural connectivity to cognition10.1016/j.tins.2007.04.004 ↗
13. Melanoma brain colonization involves the emergence of a brain-adaptive phenotype10.18632/oncoscience.11 ↗
14. Spatial components of molecular tissue biology10.1038/s41587-021-01182-1 ↗
15. Spatial biology of cancer evolution10.1038/s41576-022-00553-x ↗
16. Astrocytes facilitate melanoma brain metastasis via secretion of IL −2310.1002/path.4509 ↗
17. Space in cancer biology: its role and implications10.1016/j.trecan.2022.07.008 ↗
18. Gentles · 2022 · 549
19. Microfluidic device with reconfigurable spatial temporal gradients reveals plastic astrocyte response to stroke and reperfusion10.1039/D3LC00276D ↗
20. Griddient: a microfluidic array to generate reconfigurable gradients on-demand for spatial biology applications10.1038/s42003-023-05282-3 ↗
21. Virus-free CRISPR knockin of a chimeric antigen receptor into KLRC1 generates potent GD2-specific natural killer cells10.1016/J.YMTHE.2025.01.024 ↗
22. Generation of cerebral organoids from human pluripotent stem cells10.1038/nprot.2014.158 ↗
23. Generation of urine iPS cell lines from patients with Attention Deficit Hyperactivity Disorder (ADHD) using a non-integrative method10.1016/j.scr.2016.05.015 ↗
24. Computational fluid dynamic analysis of physical forces playing a role in brain organoid cultures in two different multiplex platforms10.1186/s12861-019-0183-y ↗
25. Short term changes in the proteome of human cerebral organoids induced by 5-MeO-DMT10.1038/s41598-017-12779-5 ↗
26. Total cellular ATP production changes with primary substrate in MCF7 breast cancer cells10.3389/fonc.2020.01703 ↗
27. Protocol for analyzing energy metabolic pathway dependency in human liver cancer cell lines10.1016/j.xpro.2024.102964 ↗
28. Impact of cellular ATP levels on cell viability in response to fluorouracil through lysophosphatidic acid (LPA) receptor-4 (LPA4) and LPA6 in colon cancer cells10.1016/j.jbior.2024.101042 ↗
29. Loss-of-function mutation in Pcsk1 increases serum APOA1 level and LCAT activity in mice10.1186/s42826-021-00111-2 ↗
30. The metabolism of cancer cells during metastasis10.1038/s41568-020-00320-2 ↗
31. Metabolic changes during carcinogenesis: potential impact on invasiveness10.1016/j.jtbi.2006.09.010 ↗
32. Heterogeneity in the metastatic microenvironment: junB-expressing microglia cells as potential drivers of melanoma brain metastasis progression10.3390/CANCERS15204979 ↗
33. Long-term characterization of activated microglia/macrophages facilitating the development of experimental brain metastasis through intravital microscopic imaging10.1186/s12974-018-1389-9 ↗
34. Famine versus feast: understanding the metabolism of tumors in vivo10.1016/j.tibs.2015.01.004 ↗
35. High ATP production fuels cancer drug resistance and metastasis: implications for mitochondrial ATP depletion therapy10.3389/fonc.2021.740720 ↗
36. Microfluidic tumor-on-a-chip model to study tumor metabolic vulnerability10.3390/ijms21239075 ↗
37. Glutamate as a neurotransmitter in the healthy brain10.1007/s00702-014-1180-8 ↗
38. The role of glutamate receptors in the regulation of the tumor microenvironment10.3389/fimmu.2023.1123841 ↗
39. Glutamate blunts cell-killing effects of neutrophils in tumor microenvironment10.1111/cas.15355 ↗
40. Glutamate in cancers: from metabolism to signaling10.7555/JBR.34.20190037 ↗
41. Pathway analysis of glutamate-mediated, calcium-related signaling in glioma progression10.1016/j.bcp.2020.113814 ↗
42. Tumor microenvironment: lactic acid promotes tumor development10.1155/2022/3119375 ↗
43. Lactate: the mediator of metabolism and immunosuppression10.3389/fendo.2022.901495 ↗
44. Microfluidic model to evaluate astrocyte activation in penumbral region following ischemic stroke10.3390/cells11152356 ↗
45. Approaches using molecular imaging technology—use of PET in clinical microdose studies10.1016/j.addr.2010.09.011 ↗
46. Where contrast agent concentration really matters—A comparison of CT and MRI10.1097/RLI.0b013e3181ea703d ↗
47. Positron emission tomography: current challenges and opportunities for technological advances in clinical and preclinical imaging systems10.1146/annurev-bioeng-071114-040723 ↗
48. [68 Ga]Ga-FAPI-46 PET for non-invasive detection of pulmonary fibrosis disease activity10.1007/s00259-022-05814-9 ↗
49. 90Y-NM600 targeted radionuclide therapy induces immunologic memory in syngeneic models of T-cell non-hodgkin’s lymphoma10.1038/s42003-019-0327-4 ↗
50. Microfluidic array for three-dimensional perfusion culture of human mammary epithelial cells10.1007/s10544-011-9545-3 ↗
51. A 3D microfluidic model for preclinical evaluation of TCR-engineered T cells against solid tumors10.1172/jci.insight.89762 ↗
52. A human organotypic microfluidic tumor model permits investigation of the interplay between patient-derived fibroblasts and breast cancer cells10.1158/0008-5472.CAN-18-2293 ↗
53. Studying the influence of angiogenesis in in vitro cancer model systems10.1016/j.addr.2015.11.004 ↗
54. Tumor-on-a-chip platform to investigate progression and drug sensitivity in cell lines and patient-derived organoids10.1039/C8LC00596F ↗
55. Chemotherapy-induced antitumor immunity requires formyl peptide receptor 110.1126/science.aad0779 ↗
56. Microfluidic-based vascularized microphysiological systems10.1039/C8LC00285A ↗
57. Evaluating CAR‐T cell therapy in a hypoxic 3D tumor model10.1002/adhm.201900001 ↗
58. Study of lung-metastasized prostate cancer cell line chemotaxis to epidermal growth factor with a BIOMEMS device10.1088/2043-6262/3/3/035007 ↗
59. Interstitial flows promote amoeboid over mesenchymal motility of breast cancer cells revealed by a three dimensional microfluidic model10.1039/C5IB00115C ↗
60. Microfluidic three-dimensional biomimetic tumor model for studying breast cancer cell migration and invasion in the presence of interstitial flow10.1016/j.cclet.2019.02.017 ↗
61. The effects of monocytes on tumor cell extravasation in a 3D vascularized microfluidic model10.1016/j.biomaterials.2018.03.005 ↗
62. The emerging landscape of spatial profiling technologies10.1038/s41576-022-00515-3 ↗
63. Redefining clinical practice through spatial profiling: a revolution in tissue analysis10.1308/rcsann.2023.0091 ↗
64. Funders: the missing link in equitable global health research?10.1371/journal.pgph.0000583 ↗
65. Equipment—UWCCC Research—UW–Madison